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Abstract
Background: Autoimmunity to brain may play a pathogenic role in autism. In autoimmune disorders, the
formation of antigen-antibody complexes triggers an inflammatory response by inducing the infiltration of
neutrophils. Local administration of recombinant progranulin, which is an anti-inflammatory neurotrophic factor,
potently inhibit neutrophilic inflammation in vivo, demonstrating that progranulin represents a crucial
inflammation-suppressing mediator. We are the first to measure plasma progranulin levels in autism.
Methods: Plasma levels of progranulin were measured, by ELISA, in 40 autistic patients, aged between 3 and
12 years, and 40 healthy-matched children.
Results: Autistic children had significantly lower plasma progranulin levels, P = 0.001. Reduced plasma progranulin
levels were found in 65% (26/40) of autistic children.
On the other hand, there was a non significant difference between plasma progranulin levels of children with mild
to moderate autism and patients with severe autism, P = 0.11.
Conclusions: Plasma progranulin levels were reduced in a subgroup of patients with autism. Progranulin
insufficiency in some patients with autism may result in many years of reduced neutrotrophic support together
with cumulative damage in association with dysregulated inflammation that may have a role in autism. However,
these data should be treated with caution until further investigations are performed, with a larger subject
population, to determine whether the decrease of plasma progranulin levels is a mere consequence of autism or
has a pathogenic role in the disease. The role of progranulin therapy should also be studied in autism.
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Background
A possible role of abnormalities in the immune system in
the pathogenesis of some neurologic disorders, including
autism, was postulated [1,2]. Autoimmunity to the central
nervous system may have a pathogenic role in autism [1].
This may be indicated by the presence of brain-specific
auto-antibodies in some autistic children [3-9]. There is
also an increase in the frequency of autoimmune disorders
among autistic families [7,10-17]. In addition, there is a
strong association between autism and the major histo-
compatibility complex for the null allele of C4B in class III
region [15,18,19].
Neutrophils belong to the body’s first line of cellular
defense and respond quickly to tissue injury and invading
microorganisms [20]. In autoimmune disorders, the
underlying pathogenic mechanism is the formation of
antigen-antibody complexes, so-called immune complexes
(ICs), which trigger an inflammatory response by inducing
the infiltration of neutrophils [21]. The subsequent stimu-
lation of neutrophils by C3b-opsonized ICs results in the
generation of reactive oxygen species (ROS) and the
release of intracellularly stored proteases leading to tissue
damage and inflammation [22]. It is therefore important
to identify the mechanisms that control the activation of
infiltrating neutrophils [23].
Progranulin, also known as proepithelin, acrogranin,
or prostate cancer cell-derived growth factor, is a
secreted glycosylated protein that undergoes proteolysis
to generate seven mutually homologous 6-kD peptides,
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called granulins or epithelins [24,25]. Progranulin is
released by a varaiety of cells and it is expressed by
epithelial cells, macrophages, and neurons [24,26]. Pro-
granulin is a growth factor implicated in tissue regenera-
tion, tumorigenesis, and inflammation [24,27,28]. An in
vitro study suggested that progranulin may function as a
neurotrophic factor [29].
Progranulin was previously shown to directly inhibit
adhesion-dependent neutrophil activation by suppressing
the production of ROS and the release of neutrophil pro-
teases in vitro. Local administration of recombinant pro-
granulin potently inhibited neutrophilic inflammation in
vivo, demonstrating that progranulin represents a crucial
inflammation-suppressing mediator [27]. This anti-
inflammatory activity is degraded by neutrophil-mediated
proteolysis of progranulin to granulin peptides. In con-
trast, granulin peptides are strongly pro-inflammatory
that enhance inflammation. Recent studies proposed pro-
granulin as a regulator of the innate immune response,
but the factors that control progranulin function are still
poorly defined [23]. Progranulin inactivation might be
involved in some autoimmune diseases such as small ves-
sel vasculitis and lupus nephritis [30].
Since autism may be one of the pediatric autoimmune
neuropsychiatric disorders, this study was the first to
investigate the plasma levels of progranulin, which is an




This case-control study was conduced on 40 children
who had classic-onset autism. The patients were fulfill-
ing the criteria for the diagnosis of autism according to
the 4th edition of the Diagnostic and Statistical Manual
of Mental Disorders [31].
The autistic group comprised 32 males and 8 females.
They were recruited from the Autism Research and Treat-
ment Center, Faculty of Medicine, King Saud University,
Riyadh, Saudi Arabia. Their ages ranged between 3 and 12
years (mean ± SD = 7.98 ± 2.59 years).
Inclusion criteria
1- Patients who had no associated neurological dis-
eases (such as cerebral palsy, tuberous sclerosis).
2- Patients who had no associated metabolic disorders
(eg. Phenylketonuria) because these associated comor-
bidities with autism may influence the results of plasma
progranulin levels.
3- Patients who were not receiving any medications.
The control group comprised 40 age- and sex-matched
apparently healthy children. They included 33 males and
7 females. They were the healthy older siblings of the
healthy children who attend the Well Baby Clinic, King
Khalid University Hospital, Faculty of Medicine, King
Saud University, Riyadh, Saudi Arabia for routine follow
up of their growth parameters. The control children were
not related to the children with autism, and demon-
strated no clinical findings suggestive of immunological
or neuropsychiatric disorders. Their ages ranged between
3 and 12 years (mean ± SD = 7.83 ± 2.64 years).
The local Ethical Committee of the Faculty of Medi-
cine, King Saud University, Riyadh, Saudi Arabia,
approved this study. In addition, an informed written
consent of participation in the study was signed by the
parents or the legal guardians of the studied subjects.
Study measurements
Clinical evaluation of autistic patients
This was based on clinical history taking from the care-
givers, clinical examination and neuropsychiatric assess-
ment. In addition, the degree of the severity of autism
was assessed by using the Childhood Autism Rating Scale
(CARS) [32] which rates the child on a scale from one to
four in each of fifteen areas (relating to people; emotional
response; imitation; body use; object use; listening
response; fear or nervousness; verbal communication;
non-verbal communication; activity level; level and con-
sistency of intellectual response; adaptation to change;
visual response; taste, smell and touch response and gen-
eral impressions). According to the scale, children who
have scored 30-36 have mild to moderate autism (n =
12), while those with scores ranging between 37 and 60
points have severe autism (n = 28).
Assessment of plasma progranulin levels
We used the human progranulin ELISA kit (R&D Systems,
Europe, Ltd.). This assay recognizes recombinant and nat-
ural human progranulin. No significant cross-reactivity or
interference was observed. To increase accuracy, all sam-
ples were analyzed twice in two independent experiments
to assess inter-assay variations and to ensure reproducibil-
ity of the observed results (P > 0.05).
Statistical analysis
The results were analyzed by the commercially available
software package (Statview, Abacus concepts, inc., Berkley,
CA, USA). The data were non-parametric, thus they were
presented as median and interquartile range (IQR). Mann-
Whitney test was used for comparison between these data.
Spearman’s rank correlation coefficient “r” was used to
determine the relationship between different variables. For
all tests, a probability (p) of less than 0.05 was considered
significant. Receiver operating characteristic (ROC) curve
is a plotting of sensitivity versus 1-specificity at different
cut-off values of the studied variable. The uppermost left
point represents the best cut-off value (based on the high-
est sensitivity with the lowest false positive results of the
studied marker) to differentiate the two groups under
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study. If the area under the curve (AUC) is > 0.5, this
means that the variable is able to differentiate the two
groups and the closer this area to 1 the better its differen-
tiating ability. The best cut-off value of plasma progranulin
was 83.5 ng/ml. AUC = 0.72, meaning that plasma progra-
nulin was a good differentiating marker between patients
and controls at this cut-off value.
Results
Autistic children had significantly lower plasma progra-
nulin levels [median (IQR) = 77.50 (19) ng/ml] than
healthy controls [median (IQR) = 87.00 (81) ng/ml], P =
0.001 (Figure 1). Reduced plasma progranulin levels
were found in 65% (26/40) of autistic children.
On the other hand, there was a non significant differ-
ence between plasma progranulin levels of children with
mild to moderate autism and patients with severe aut-
ism, P = 0.11 (table 1). In addition, plasma progranulin
levels of autistic patients had no significant correlations
with CARS (P = 0.45).
There was a non significant difference between plasma
progranulin levels of male and female autistic patients, P =
0.84, (table 1). Plasma progranulin levels of autistic
patients had no significant correlations with the age of
autistic children (P = 0.82).
Discussion
Aetiology of autism presents many challenging issues and
it has become an area of a significant controversy [33].
Autism may, in part, involve an autoimmune pathogenesis
[1]. Neutrophils have a pathogenic role in autoimmunity
[34]. Progranulin inhibits neutrophil activation and inflam-
matory activity, thus it represents a crucial inflammation-
suppressing mediator [27].
In our series, autistic children had significantly lower
plasma progranulin levels than healthy controls, P =
0.001. Reduced plasma progranulin levels were found in
65% (26/40) of autistic children. We could not trace data
in the literature concerning progranulin levels in the
blood of autistic children to compare our results. This
study was the first to investigate plasma progranulin
levels in autistic children.
Recently, much attention has been paid to the functional
role of progranulin in the central nervous system because
progranulin plays a key role in disease progression in neu-
rodegenerative diseases [35-42]. Mutations in progranulin
gene were identified as the cause of some forms of autoso-
mal dominant tau-negative frontotemporal lobar degen-
eration (FTLD) [35,36], which is represented by severe
atrophy in the frontal and temporal lobes of the brain.
Therefore, haploinsufficiency with reduced progranulin-
induced neuronal survival is thought to cause neurodegen-
eration [37]. Recent studies raise the possibility that FTLD
may result in part from brain damage arising from the
combination of dysregulated inflammation and heightened
neuronal vulnerability as a result of reduced progranulin
levels [43]. Progranulin level in the serum or the plasma is
a reliable biomarker for diagnosis and early detection of
FTLD caused by progranulin null mutations [44,45].
Progranulin protein is strongly reduced (up to 3.93-fold)
both in plasma and CSF of affected and unaffected at risk
subjects of families carrying the FTLD associated progra-
nulin gene mutations. The dosage of plasma progranulin
is a useful tool for a quick and inexpensive large-scale
screening of carriers of progranulin mutations and for
monitoring future treatments that might boost the level of
this protein [46].
Progranulin has been implicated in inflammation, but its
receptors remain unidentified. It was reported that progra-
nulin bound directly to tumor necrosis factor receptors
(TNFRs) and disturbed the TNFa-TNFR interaction. Pro-
granulin-deficient mice were susceptible to collagen-
induced arthritis, and administration of progranulin
reversed inflammatory arthritis. Atsttrin, an engineered
protein composed of three progranulin fragments, exhib-
ited selective TNFR binding. Progranulin and Atsttrin pre-
vented inflammation in multiple arthritis mouse models
and inhibited TNFa-activated intracellular signaling. Col-
lectively, these findings demonstrate that progranulin is a
ligand of TNFR, an antagonist of TNFa signaling, and
plays a critical role in the pathogenesis of inflammatory
arthritis in mice [47,48]. In addition, macrophages from
progranulin-deficient mice secrete less interleukin-10 and
more inflammatory cytokines when exposed to bacterial
Figure 1 Plasma progranulin levels in autistic patients and
healthy children. Median value for each group is shown by a
horizontal bar.
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lipopolysaccharide. Progranulin-deficient mice responded
to infection with exaggerated inflammation. Ex vivo, pro-
granulin-deficient hippocampal neurons were more
vulnerable to metabolic stress. So, progranulin is a key reg-
ulator of inflammation and plays critical roles in both host
defense and neuronal integrity [43].
Autism is recognized as having an inflammatory compo-
nent. Post-mortem brain samples from patients with aut-
ism display neuroglial activation and an increase of the
levels of inflammatory markers in cerebrospinal fluid,
although little is known about the underlying molecular
mechanisms [49]. Progranulin is a neuroprotective agent
against neuroinflammation that often acts through the
extracellular signal-regulated kinase and phopshatidylino-
sitol-3-kinases pathways [50]. Thus, one should expect an
increase in the production of the anti-inflammatory pro-
granulin, which is a key regulator of inflammation, in aut-
ism. However, in the current study, the possible triggered
inflammatory response in autism did not result in the
increase of the production of the anti-inflammatory pro-
granulin. This may be attributable to the presence of loss-
of-function mutations in the progranulin gene in some
patients with autism. However these data should be trea-
ted with a great caution till wide-scale studies investigating
progranulin gene mutations in relation to plasma progra-
nulin levels in autistic children are performed.
A recent study reported a significant elevation of CSF
concentrations of progranulin in patients with relapsing-
remitting multiple sclerosis (MS) during relapses com-
pared with patients with relapsing-remitting MS during
remissions and with non-inflammatory controls [51]. The
elevation of CSF concentrations of progranulin in MS
during relapse may be a local defense mechanism against
inflammation by increasing the production of the anti-
inflammatory progranulin to regulate the inflammatory
process. Thus, the triggered inflammatory response in
MS may result in increased progranulin levels in CSF of
MS patients. This may indicate that progranulin gene
mutations and progranulin deficiency may not have a
role in MS.
Therefore in many inflammatory conditions such as MS,
the increase of the production of the anti-inflammatory
progranulin is expected to control the inflammatory pro-
cess [51]. However, in some neuroinflammatory diseases,
in which reduced progranulin levels may have a patho-
genic role such as FTLD, mutations in progranulin gene
with a subsequent progranulin deficiency may result in
brain damage due to dysregulated inflammation secondary
to reduced progranulin production [43]. This may be also
the case in autism. A recent study reported the utility of
prospective serum screening of progranulin as a surrogate
diagnostic marker for progranulin gene mutations. It con-
cluded that serum testing of progranulin is an accurate
and cost effective means of predicting progranulin gene
mutations in FTLD [52].
In the present work, there was a non significant differ-
ence between plasma progranulin levels of children with
mild to moderate autism and patients with severe aut-
ism, P = 0.11. In addition, plasma progranulin levels of
autistic patients had no significant correlations with
CARS. These results may indicate that plasma progranu-
lin levels were reduced in autistic patients regardless the
degree of the disease severity.
A prominent role of progranulin in the regulation of
inflammation was suggested by the discovery that neutro-
phil elastase and macrophage-derived secretory leukocyte
protease inhibitor (SLPI) promote and prevent, respec-
tively, the conversion of progranulin to granulin, and that
recombinant progranulin inhibits neutrophil activation,
whereas granulin promotes epithelial cell generation of
neutrophil chemoattractants [27].
It is speculated that the autoimmune reaction to mye-
lin in autism may result in the release of some neuronal
antigens. These antigens, through the activation of
inflammatory cells, could initiate autoimmune reactions
with the production of brain-specific auto-antibodies in
genetically susceptible individuals. These antibodies may
cross the blood brain barrier and combine with brain
tissue antigens forming immune complexes, thus further
damaging the neurological tissue [53].
In autoimmune disorders, the formation of antigen-anti-
body immune complexes trigger an inflammatory response
by inducing the infiltration of neutrophils [21] with subse-
quent ROS and the release of intracellularly stored pro-
teases in neutrophils leading to tissue damage and
inflammation [22]. In addition, neutrophil cells have been
considered mainly as innate immune cells directed against
microbial threats. Their serine proteases (neutrophil
Table 1 Plasma progranulin levels in relation to the degree of the severity of autism and the gender of the autistic
patients
Patients with autism Plasma progranulin (ng/ml)
Median (IQR)
Z-value P-value
Mild to moderate autism (n = 12) 74 (21) 0.52 0.61
Severe autism (n = 28) 79.5 (22)
Male autistic patients (n = 32) 78 (19) 0.2 0.84
Female autistic patients (n = 8) 75 (34)
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elastase and proteinase 3) are released at sites of inflamma-
tion and act as regulators of cell signaling and immune reg-
ulation. Neutrophil serine proteases act as alternative
processing enzymes of pro-inflammatory cytokines IL-1b
and IL-18 in vivo and modulate other inflammation-related
control mechanisms such as progranulin inactivation in
small vessel vasculitis and lupus nephritis [30]. We could
not trace data in the literature regarding the neutrophil
function in autistic patients, so we suggest that studies
should be conducted to investigate neutrophil function in
these patients. Since progranulin deficiency can promote
the induction of autoimmunity through stimulation of neu-
trophil activation, the relationship between the low plasma
progranulin levels and the induction of the production of
brain-specific auto-antibodies in some autistic patients
should also be studied.
In the central nervous system, progranulin is widely
expressed during early neural development but later on, its
expression becomes restricted to specific neuronal popula-
tions including cortical neurons in several layers, pyramidal
cell layer and dentate gyrus of the hippocampus, ventrome-
dial and arcuate nuclei of the hypothalamus, amygdale, and
Purkinje cell layer in the cerebellum [26,37,54]. Recent stu-
dies suggest that progranulin is involved in neurotrophic
activity and neuroinflammation [37,55]. An in vitro study
reported that progranulin enhanced the neuronal survival
and neurite length in cultured cortical and motor neurons.
Interestingly, these effects were abolished by coadministra-
tion of SLPI, suggesiting that progranulin/granulin conver-
sion plays a crucial role in their actions. In the central
nervous system, SLPI has been known to be expressed in
reactive astrocytes [56].
Therefore, progranulin insufficiency in some patients
with autism may result in many years of reduced neutro-
trophic support together with cumulative damage in
association with dysregulated inflammation that may
have a role in autism. However, we suggest that further
studies, with a larger subject population, should be con-
ducted to determine whether the decrease of plasma pro-
granulin levels is a mere consequence of autism or has a
pathogenic role in the disease.
Conclusions
Plasma progranulin levels were reduced in a subgroup of
patients with autism. Progranulin insufficiency in some
patients with autism may result in many years of reduced
neutrotrophic support together with cumulative damage
in association with dysregulated inflammation that may
have a role in autism. However, these data should be trea-
ted with caution until further investigations are performed,
with a larger subject population, to determine whether the
decrease of plasma progranulin levels is a mere conse-
quence of autism or has a pathogenic role in the disease.
In addition, wide-scale studies investigating progranulin
gene mutations in relation to plasma progranulin levels
and autoimmunity in autistic children are warranted. The
role of progranulin therapy should also be studied in
autism.
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